- The impact of the COVID-19 pandemic on health related
- quality of life in head and neck cancer survivors: an
- 3 observational cohort study
- B.I. Lissenberg-Witte<sup>1,2</sup>, F. Jansen<sup>3,4,5</sup>, R.J. Baatenburg de Jong<sup>6</sup>, F. Lamers<sup>4,7</sup>, C.R. Leemans<sup>3,5</sup>, S.F.
   Oosting<sup>8</sup>, R.P. Takes<sup>9</sup>, I.M. Verdonck-de Leeuw<sup>3,4,5,10</sup>
- 8 Amsterdam UMC location Vrije Universiteit, Epidemiology and Data Science, Amsterdam, the Netherlands
- 9 <sup>2</sup>Amsterdam Public Health Research Institute, Methodology, Amsterdam, the Netherlands
- 10 <sup>3</sup>Amsterdam UMC location Vrije Universiteit, Otolaryngology Head and Neck Surgery, Amsterdam, the
- 11 Netherlands

- 12 <sup>4</sup>Amsterdam Public Health Research Institute, Mental Health, Amsterdam, the Netherlands
- 13 <sup>5</sup>Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, Amsterdam, the Netherlands
- 14 <sup>6</sup>Department of Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
- 15 <sup>7</sup>Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Psychiatry, Amsterdam, The
- 16 Netherlands
- 17 <sup>8</sup>University of Groningen, Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1,
- 18 9700 RB Groningen, The Netherlands
- 19 <sup>9</sup>Department of Otorhinolaryngology-Head and Neck Surgery, Radboud University Medical Center, Nijmegen,
- 20 The Netherlands

24 25 26

27

- 21 <sup>10</sup>Vrije Universiteit Amsterdam, Department Clinical, Neuro and Developmental Psychology, Van der
- Boechorststraat 7-9, Amsterdam, The Netherlands
  - Corresponding author: Birgit I. Lissenberg-Witte (b.lissenberg@amsterdamumc.nl)

**Abstract** 

- 30 Background: Physical, psychological, and social aspects of health-related quality of life (HRQOL)
- among head and neck cancer (HNC) survivors may be more affected during the COVID-19 pandemic
- 32 than before the pandemic. However, the impact is not yet understood well.
- 33 Methods: Prospectively collected data from the NETherlands OUality of life and Blomedical Cohort
- 34 study in HNC were used. All patients were diagnosed and treated before the COVID-19 pandemic.
- 35 Patient reported outcome measures (PROMs) collected 24 and 36 months after treatment (M24 and
- 36 M36) were compared between survivors who completed both assessments before the COVID-19
- 37 pandemic and those who completed M24 before but M36 during the pandemic. Personal, clinical,
- 38 physical, psychological, social, and lifestyle characteristics of the survivors assessed at baseline or
- 39 M24 were investigated as potential effect modifiers.
- 40 Results: In total, 318 HNC survivors were included, of which 199 completed both M24 and M36
- 41 before the COVID-19 pandemic and 119 completed M24 before but M36 during the pandemic.
- 42 Changes in HRQOL between 24 and 36 months follow-up did not differ between the two groups for
- any of the PROMs. However, in some subgroups of HNC survivors the COVID-19 pandemic negatively
- 44 affected the course of HRQOL for several PROMs while it positively affected the course of HRQOL for
- 45 other PROMs.
- 46 Conclusions: The COVID-19 pandemic did not affect HRQOL in HNC survivors in general, but some
- subgroups were affected in a positive and others in a negative way.
- 48 Funding: This work was supported by the Dutch Cancer Society [grant number VU 2013-5930] and
- 49 the Dutch Cancer Society, Alpe Young Investigator Grant [grant number 12820].

50 Introduction 51 Head and neck cancer (HNC) and its treatment negatively affect the physical, psychological, and 52 social aspects of health-related quality of life (HRQOL) not only before and during treatment but 53 also in long-term survivors [1-6]. It may be that HRQOL of HNC survivors is even more affected in 54 the setting of the COVID-19 pandemic which had an enormous health care, societal and economic 55 impact, but this is not yet understood very well. Previous studies among cancer patients reported a 56 negative impact of the COVID-19 pandemic on HRQOL related to physical [7, 8], psychological [7, 9-57 12], and social functioning [7, 10, 12]. Other studies found no effect of the COVID-19 pandemic on 58 HRQOL [13, 14] or showed an improvement in physical, role, and social functioning [12] and less 59 loneliness [10]. Several studies investigated possible effects of the COVID-19 pandemic on HRQOL among HNC patients specifically [15-19]. Gallo et al. reported a negative effect on physical, role 60 and emotional functioning and no effect on cognitive and social functioning, global quality of life, 61 62 or cancer related symptoms [15]. Hamilton et al. found a negative impact on cancer related 63 symptoms [16]. Kirtane et al. conducted a qualitative study and found a negative impact of the 64 COVID-19 pandemic on psychological distress and social isolation [17]. In contrast, Rodrigues-65 Oliveira et al. found no differences on symptoms of anxiety and depression between HNC patients during radiotherapy before or after the COVID-19 pandemic [18]. Büntzel et al. reported a negative 66 67 effect on physical and psychological function, and isolation, and a positive effect on relations with 68 family and nature [19]. 69 An explanation for these different and sometimes contradictory findings on the impact of the 70 COVID-19 pandemic among cancer patients might be that most investigators used cross-sectional 71 study designs, and compared the results to reference values or historical cohorts [9-11, 13-19]. Only 72 few studies investigated HRQOL longitudinally, in which part of the measurements were carried out 73 before the COVID-19 pandemic and others during the pandemic [8, 12] or in which cancer patients 74 were prospectively followed during the COVID-19 pandemic [7]. Another explanation for the various 75 previous findings might be that the COVID-19 pandemic affected some patients more than others. Factors that might moderate the impact of the COVID-19 pandemic are age, sex, educational level, 76 77 marital status, household composition, type and stage of cancer, treatment intent, physical health, 78 iob security, and pre-existing psychological problems [7, 9, 14]. Thus far, studies longitudinally 79 investigating the effect of the COVID-19 pandemic on HRQOL among HNC survivors are lacking. 80 The aim of this study is to prospectively investigate the impact of the COVID-19 pandemic on HRQOL 81 among HNC survivors. The following two research questions are addressed: 1) Did the COVID-19 82 pandemic change the course of HRQOL over time (disease and tumor specific HRQOL, physical 83 activity, symptoms of distress, anxiety, and depression, fear of cancer recurrence, and loneliness), 84 2) Can subgroups of HNC patients (in terms of personal, clinical, psychological, physical, social, 85 lifestyle, and disease-related factors) be identified in which the course of HRQOL is positively or 86 negatively affected as a consequence of the COVID-19 pandemic.

88 Methods 89 Study design and patients 90 Data and samples were used from the NETherlands QUality of life and Blomedical Cohort study in 91 HNC (NET-OUBIC), a prospective cohort study among 739 HNC patients. Patients were recruited 92 between March 2014 and June 2018. Patients were included before start of treatment (baseline) 93 and data was collected at baseline (T0) and 3, 6, 12, 24, and 36 months (M3, M6, M12, M24 and M36) 94 after end of treatment. Data was derived from an electronic case report form (eCRF) designed for 95 NET-QUBIC, patient reported outcome measures (PROMs) and fieldwork assessments. Newly 96 diagnosed HNC patients were included in NET-QUBIC if they were i) 18 years or older, ii) treated 97 with curative intent for cancer of the oral cavity, oropharynx, hypopharynx, larynx, or unknown 98 primary, and iii) able to write, read, and speak Dutch. Patients were excluded if they i) were unable 99 to understand the questions or test instructions, ii) had severe psychiatric comorbidities (i.e. 100 schizophrenia, Korsakoff's syndrome, dementia), or iii) were unable to understand informed 101 consent. In the current study, HNC survivors were included if they completed at least one PROM at 102 M36. Furthermore, only the T0, M24 and M36 PROMs were used. PROMs completed before March 14<sup>th</sup> 103 2020 were considered 'before COVID-19' while PROMs completed on or after March 14th 2020 were 104 considered 'during COVID-19'. Consent procedures were approved by the Medical Ethical Committee 105 of Amsterdam UMC location VUmc (METc VUmc 2013.301 (A2018.307)-NL45051.029.13)) and all 106 participating hospitals and followed the Dutch Medical Research Involving Human Subjects Act. All 107 included survivors signed informed consent. 108 Details of the key components of NET-QUBIC were published previously: the study population 109 (including retention, attrition and potential selection bias), eCRF, the outcome assessment 110 protocol, biobanking protocol, data management (collection and storage), and data and sample dissemination procedures [20, 21]. The STROBE guidelines were adhered when reporting the results 111 112 of this study [22]. As this was a not pre-planned post-hoc analysis of the original NET-QUBIC, no 113 formal sample size calculation for the current study has been performed. 114 115 Outcome measures 116 Disease specific and tumor specific HRQOL were measured with the European Organisation for 117 Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and EORTC-118 QLQ-HN35, respectively. The EORTC QLQ-C30 is a 30-item questionnaire and consists of one global 119 quality of life scale (QL), five functional scales (physical, role, emotional, cognitive and social 120 functioning), three symptom scales (fatigue, nausea and vomiting, and pain) and six single item 121 symptoms (dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties). A 122 sum score (SumSC) is based on the five functional scales, the three symptom scales and five of the 123 six single items (financial toxicity is not included) [23-25]. The EORTC-QLQ-HN35 consists of seven 124 HNC specific symptoms (pain, swallowing, senses, speech, social eating, social contact, and 125 sexuality) and ten single item symptoms (problems with teeth, dry mouth, sticky saliva, cough,

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

opening the mouth wide, weight loss, weight gain, use of nutritional supplements, feeding tubes, and painkillers) [26]. QLQ-C30 and QLQ-HN35 Items were scored on a 4-point Likert scale and scores for each of the subscales range from 0 to 100, where higher scores on QL, SumSC and the functional scales indicate better HRQOL and functioning while higher scores on the symptom scales indicate more symptoms. Physical activity was measured with the Physical Activity Scale for the Elderly (PASE). The PASE is a 13-item questionnaire measuring duration and frequency of leisure time, household and workrelated physical activities [27, 28]. Subscale scores for each of the domains were calculated as well as a total score. Higher scores on the subscales and total score indicate more physical activity. The total activity score was also categorized as very poor, poor, fair, good, very good and excellent. Distress and symptoms of anxiety and depression were measured using the Hospital Anxiety and Depression Scale (HADS). The HADS is a 14-item questionnaire measuring emotional distress and includes a total scale (HADS-T) and an anxiety (HADS-A) and depression (HADS-D) subscale [29]. Items were scored on a 4-point Likert scale and scores for each of the subscales range from 0 to 21, where higher scores indicate higher extent of distress, depression or anxiety symptoms. Fear of cancer recurrence was measured with the Cancer Worry Scale (CWS). The CWS is an 8-item questionnaire measuring concerns about developing cancer or developing cancer again and the effect of these concerns on daily life [30]. Items were scored on a 4-point Likert scale, and a total scale score is calculated by summing all items, resulting in a total scale score ranging from 8 to 32. A higher score indicates higher extent of fear of cancer recurrence. Loneliness was measured with the De Jong Gierveld Loneliness Scale (De Jong Gierveld). The De Jong Gierveld is an 11-item questionnaire measuring emotional and social loneliness [31, 32]. Items were scored on a 3-point Likert scale. Scores for emotional loneliness range from 0 to 6 and scores for social loneliness range from 0 to 5, where higher scores indicate higher loneliness. A total loneliness score was calculated by summing the scores of the two scales. The total loneliness score was also categorized as not lonely (score 0 to 2), moderate (score 3 to 8), severe (score 9 or 10) and very severe (score 11) [33]. Influencing factors Data on personal, clinical, physical, psychological, social, and lifestyle characteristics were collected from eCRF data, PROMs and fieldwork assessments. Personal factors (assessed at baseline) included age, sex, educational level (low, middle or high), living status (alone or cohabiting), marital status (married or not married), and personality. Personality was assessed by the extraversion subscale of the 60-item NEO Five Factor Inventory (NEO-FFI) questionnaire [34]. Items are scored on a 5-point Likert scale. The extraversion subscale consists of 12 item and ranges from 12 to 60, where a higher score indicates a higher level of extraversion.

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181 182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

Clinical factors included tumor location (oral cavity, oropharynx, hypopharynx, larynx or unknown primary), tumor stage (I/II or III/IV), treatment modality (single or multimodality treatment), World Health Organization (WHO) performance status (0, able to carry out all normal activity without restriction or ≥1, restricted in normal activities), comorbidity and cancer progression at 24 months follow-up. Comorbidity was assessed by the 27-item Adult Comorbidity Evaluation-27 (ACE-27) Index, which categorizes comorbidity as none, mild, moderate and severe [35]. Cancer progression status between end of treatment and M24 was categorized as residual disease, recurrence and/or second primary tumor at M24 or none of those at M24. Physical impairments in instrumental activities in daily life was assessed by the Instrumental Activities of Daily Living (IADL) questionnaire [36]. Psychological characteristics included the presence of a major depressive disorder in the past year at M24, and presence of a lifetime major depressive disorder at M24. Presence of a major depressive disorder in the past year was assessed with the Composite International Diagnostic Interview (CIDI), which is based on DSM-IV criteria [37]. The CIDI was assessed yearly during the fieldwork assessment, i.e. at T0, M12 and 24. At T0, presence of a lifetime major depressive disorder was also assessed. A lifetime major depressive disorder was scored as present in case it was already present at baseline or when a major depressive disorder in the past year was diagnosed during the CIDI at M12 and/or M24. Having paid work (yes or no) was assessed by the iMTA productivity cost questionnaire at baseline and at M24. Lifestyle-related factors included excessive alcohol consumption (categorized as no or yes (at least 14 (women) or 21 (men) glasses of alcohol per week)), smoking behavior (categorized as current smoker or never smoker and former smoker), and body mass index (BMI) at 24 months. Statistical analyses Data is described by number and frequency in case of categorical variables and by mean and standard deviation (SD) in case of continuous variables. Differences in baseline characteristics between survivors who completed M36 before COVID-19 and survivors who completed M36 during COVID-19 as well as between survivors included in the current study and the other NET-QUBIC participants were analyzed by the chi-square test or the independent sample t-test, depending on the distribution of the variable. Difference in change from M24 to M436 of continuous PROMs between the groups were analyzed by linear mixed effects models, with fixed effect for group, follow-up measurement (M24 or M36) and their two-way interaction and a random intercept for subject. Differences in change of dichotomous or categorical PROMs were analyzed by generalized estimating equations (GEE), with a logit-link function (dichotomous PROMs) or cumulative logit-link function (categorical PROMs). Reported effect sizes, with corresponding 95% confidence intervals (CI) for the change between M24 and M36 include the difference between groups in change between

M24 and M36 based on the estimated marginal means for continuous PROMs and odds ratios (OR) for dichotomous and categorical outcomes.

The modifying effect of potential influencing factors for the change between M24 and M36 was also analyzed using linear mixed effects model, including fixed effects for group, measurement and the potential effect modifier, all two-way interactions and the three-way interaction as well as a random intercept for subject. In case of multiple effect modifiers for one PROM, analyses were repeated after stratification for the factor with the lowest p-value (below 0.05) for the three-way interaction. Continuous effect modifiers were stratified by median split. Stratification was only done in case each stratum and each group (completely before COVID or partly during COVID) contained at least 20 survivors. All analyses were performed in SPSS version 28 (IBM Corp., Armonk, NY, USA). The two-sided significance level was set at 0.01, to account for the large number of PROMs analyzed.

Results

212

249

213 Study population 214 Of the 739 participants included in NET-QUBIC, 487 were known to be alive and included in NET-215 QUBIC at M24 of which 345 survivors completed at least one PROM questionnaire at the M36 216 assessment, 199 before the COVID-19 pandemic and 146 during the pandemic. Twenty-seven of 217 these 146 survivors also filled in the questionnaires at M24 during the pandemic, and were excluded 218 form analyses resulting in 119 survivors in the group with the M36 assessment during the pandemic 219 (Figure 1). Baseline characteristics, stratified by group, are displayed in Table 1. There were no 220 significant difference in characteristics between the groups. HNC survivors included in the current 221 study (n=318) had lower comorbidity and less often a lifetime major depressive disorder at M24 222 compared to HNC survivors who were not included (n=142) in the current study (Supplementary 223 Table 1). 224 The course of HRQOL in relation to the COVID-19 pandemic 225 There were no statistically significant differences in the change of PROMs between 24 and 36 226 months follow-up between survivors who completed all PROMs before COVID-19 and those who 227 completed the M36 assessment during COVID-19 (Table 2 and Supplemental Tables 2 and 3). 228 For 31 of the 46 PROMs, one or more factors were identified that showed a different effect of the 229 COVID-19 pandemic on the change of HRQOL between M24 and M36 (p<0.05; Supplemental Table 4). 230 After stratification, the most important factors (with a p-value in at least one of the subgroups 231 <0.01) were: gender, living status at baseline, treatment modality, comorbidity, cancer progression 232 status at M24, presence of a lifetime major depressive disorder at M24, and BMI at M24 (Figure 2; 233 Supplemental Table 5). Females deteriorated in PASE total score during COVID-19 while they 234 improved before COVID-19 (categorical) (OR: 0.25, 95% CI: [0.093; 0.68], p=0.007). Survivors living 235 alone at baseline improved on EORTC-HN35 painkiller use during COVID-19 while they deteriorated 236 before COVID-19 (OR: 3.5, 95% CI [1.5; 8.1], p=0.003). HNC survivors treated by multimodality 237 treatment who completed M36 during COVID-19 showed a deterioration on the EORTC-C30 loss of 238 appetite scale whereas survivors who completed M36 before COVID-19 improved (effect size: -8.5, 239 95% CI [-13.7; -3.4], p=0.001). Survivors with residual disease, recurrence and/or second primary 240 tumor at M24 who completed M36 during COVID-19 improved on the EORTC-C30 financial problems 241 scale while survivors before COVID-19 deteriorated (effect size: 14.9, 95% CI: [5.4; 24.5], p=0.003). 242 Survivors with moderate and severe comorbidity deteriorated on the EORTC-HN35 swallowing scale 243 during COVID-19 while survivors before COVID-19 improved (effect size: -10.2, 95% CI [-16.5; -3.9], 244 p=0.002). Survivors with a lifetime major depressive disorder present at M24 deteriorated in fear of 245 recurrence during COVID-19 while they improved before COVID-19 (effect size: -3.0, 95% CI: [-5.1; -246 0.84], p=0.007). Finally, survivors with a BMI at M24 above the median improved on emotional 247 loneliness during COVID-19 while they deteriorated before COVID-19 (effect size: -0.72, 95% CI: -248 1.2; -0.28], p=0.002).

250 Discussion 251 Over all, the COVID-19 pandemic did not influence the change in HRQOL between 24 and 36 months 252 after treatment in HNC survivors. However, in some subgroups of HNC survivors the COVID-19 253 pandemic had a negative effect on some PROMs while in other groups there was a positive effect. 254 The COVID-19 pandemic had a negative effect on females (worsening of physical activity), survivors 255 treated with multimodality treatment (worsening of appetite loss), survivors with comorbidity 256 (worsening of swallowing problems), survivors with a history of a major depressive disorder 257 (worsening of fear of recurrence), and survivors with a high BMI (worsening of emotional loneliness). 258 The COVID-19 pandemic had a positive effect on survivors living alone (decrease of painkiller use) 259 and on survivors with disease progression (decrease of financial problems). Previous studies also 260 reported that sex and pre-existing psychological problems moderate the impact of the COVID-19 261 pandemic [7, 9, 14]. Furthermore, these studies suggested that also age, educational level, marital 262 status, household composition, type and stage of cancer, treatment intent, and physical health 263 might moderate the effect of the COVID-19 pandemic but this was not confirmed by the current 264 study [7, 9, 14]. 265 An explanation for the negative and positive effects of the COVID-19 pandemic among subgroups of 266 HNC survivors might be an altered and unequal access to follow-up or supportive care during the 267 COVID-19 pandemic [7, 8, 17, 38, 39]. Among colorectal cancer survivors in follow-up care during 268 the COVID-19 pandemic, role, emotional and social functioning, fatigue, sleep disturbance, and 269 anxiety was worse in those survivors who had hospital visits canceled, postponed, or changed into 270 digital care, compared with survivors without changes in their cancer care planning [13]. In 271 contrast, a systematic review on studies investigating the effect of a reduction in follow-up 272 frequency during the COVID-19 pandemic among breast cancer patients, showed no adverse effect 273 on HRQOL (nor on survival) but improved cost-effectiveness of follow-up care. Four RCTs that 274 investigated follow-up on-demand versus scheduled follow-up visits found no statistically significant 275 differences in HRQOL [40]. What we learned from the COVID-19 pandemic is that supportive care 276 services were capable to make significant changes in the provision of their care in a short period of 277 time, and that eHealth was often used as integrated part of supportive care. However, it is known 278 that some cancer survivors benefit more from eHealth than others [41]. HNC survivors may also have 279 used peer support but a survey among health care professionals in the UK demonstrated that 280 different types of peer support are available but that referral to peer support is complex and divers 281 [42]. 282 The key strength of this study is the prospective longitudinal research design. A limitation is that all 283 HNC survivors were included and finished their primary treatment for HNC before the COVID-19 284 pandemic, and the results cannot be generalized to those who were diagnosed and treated during 285 the COVID-19 pandemic. Also, for some variables, data were only available at baseline while their 286 situation may have changed two years later (e.g. marital status). Moreover, we investigated many 287 PROMs, and although we accounted for this by setting the significance level to 0.01, some of our

results could have been significant by chance. Finally, we do not know whether participating HNC

survivors were diagnosed with COVID-19. Cancer patients in general have higher odds to develop severe COVID-19 and to die of the consequences [43].

In conclusion, the course of HRQOL between 24 and 36 months after treatment in HNC survivors in general was not affected by the COVID-19 pandemic. However, the COVID-19 pandemic did change the course of some HRQOL domains or symptoms over time in some subgroups of HNC survivors. The development of personalized supportive care programs including regular care, eHealth, and peer support, tailored to the needs of the individual survivor may help to overcome disparities among HNC survivors.

299

300

301

302

303

304

305

306

307

308 309

310

311

312

313

314

315316

317

318

319

320

321

322

323

324

325

326

327 328

329

330

331

**Funding** This work was supported by the Dutch Cancer Society [grant number VU 2013-5930] and the Dutch Cancer Society, Alpe Young Investigator Grant [grant number 12820]. The funding body had no role in the design of the study and collection, analysis, and interpretation of data nor in writing the manuscript. Competing interests BLW: none FJ: received funding from the Dutch Cancer Society, Alpe Young Investigator Grant [grant number 12820]. All payments were made to the institution. FL: received funding from the Dutch Cancer Society [grant numbers VU2017-8288 and 11839]. All payments were made to the institution. CRL: none SFO: received funding from Celidex Therapeutics, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Merck and participated in the Data Safety Monitoring Board or Advisory Board of GenMab and Bristol Myers Squibb. All payments were made to the institution. RPT: none IMVdL: received funding from the Dutch Cancer Society (grant number VU 2013-5930). All payments were made to the institution. Data availability The dataset generated and analyzed (including a deindentified version of it) during the current study is not publicly available as the collection and integration of large amounts of personal, biological, genetic and diagnostic information precludes open access to the NET-QUBIC research data. Data are available from the corresponding author on reasonable request. On the NET-QUBIC website (www.kubusproject.nl) is described how NET-QUBIC data are made available for the research community. In short, a research proposal has to be submitted to the NET-QUBIC steering committee. The researcher has to be a member of the NET-QUBIC consortium, or a consortium member has to collaborate in the project. The NET-QUBIC steering committee will judge the proposal. The SPSS syntax of the analyses in this study are publically available on GitHub: https://github.com/b-lissenberg/COVID-and-cancer.

## References

332

353

355

359

- 333 Goyal, N., et al., Head and neck cancer survivorship consensus statement from the American 334 Head and Neck Society. Laryngoscope Investig Otolaryngol, 2022. 7(1): p. 70-92.
- 335 Nguyen, N.A. and J. Ringash, Head and Neck Cancer Survivorship Care: A Review of the Current 336 Guidelines and Remaining Unmet Needs. Curr Treat Options Oncol, 2018. 19(8): p. 44.
- 337 Ringash, J., et al., Head and Neck Cancer Survivorship: Learning the Needs, Meeting the 338 Needs. Semin Radiat Oncol, 2018. 28(1): p. 64-74.
- 339 Hammerlid, E., et al., Prospective, longitudinal quality-of-life study of patients with head and 340 neck cancer: a feasibility study including the EORTC QLQ-C30. Otolaryngol Head Neck Surg, 341 1997. 116(6): p. 666-73.
- 342 Hammerlid, E., et al., Health-related quality of life three years after diagnosis of head and 343 neck cancer — a longitudinal study. Head & Neck, 2001. 23(2): p. 113-25.
- 344 Bjordal, K., et al., A Prospective Study of Quality of Life in Head and Neck Cancer Patients. 345 Part II: longitudinal data. Laryngoscope 2001. 111(8): p. 1440-52.
- de Jaeghere, E.A., et al., Mental Health and Quality of Life among Patients with Cancer during 346 347 the SARS-CoV-2 Pandemic: Results from the Longitudinal ONCOVID Survey Study. Cancers 348 (Basel), 2022. 14(4).
- 349 Tabaczynski, A., et al., Changes in physical activity and associations with quality of life among 350 a global sample of cancer survivors during the COVID-19 pandemic. J Cancer Surviv, 2022.
- 351 Momenimovahed, Z., et al., Psychological Distress Among Cancer Patients During COVID-19 352 Pandemic in the World: A Systematic Review. Front Psychol, 2021. 12: p. 682154.
- 10. van de Poll-Franse, L.V., et al., Perceived care and well-being of patients with cancer and 354 matched norm participants in the COVID-19 crisis: results of a survey of participants in the Dutch PROFILES registry. JAMA Oncol, 2021. 7(2).
- 356 11. Park, J., S. Kim, and J. Heo, Aspects of Psychiatric Comorbidities in Breast Cancer Patients in 357 Tertiary Hospitals Due to COVID-19 Outbreak in South Korea: A Single Center Longitudinal 358 Cohort Study. Medicina (Kaunas), 2022. 58(5).
  - 12. Bargon, C.A., et al., Impact of the COVID-19 Pandemic on Patient-Reported Outcomes of Breast Cancer Patients and Survivors. JNCI Cancer Spectr, 2021. 5(1): p. pkaa104.
- 361 13. Koinig, K.A., et al., The cancer patient's perspective of COVID-19-induced distress-A cross-362 sectional study and a longitudinal comparison of HRQOL assessed before and during the 363 pandemic. Cancer Med, 2021. 10(12): p. 3928-3937.
- 364 14. Petrillo, L.A., et al., Health-Related Quality of Life and Depression Symptoms in a Cross 365 Section of Patients with Advanced Lung Cancer before and during the COVID-19 Pandemic. J 366 Palliat Med, 2022.
- 367 15. Gallo, O., et al., The impact of the COVID-19 pandemic on the quality of life of head and neck 368 cancer survivors. Support Care Cancer, 2021. 29(11): p. 6297-304.
- 369 16. Hamilton, S.N., et al., Patient-reported outcomes and complications during head and neck 370 cancer radiotherapy before versus during the COVID-19 pandemic. Support Care Cancer, 2022. 371 30(3): p. 2745-53.
- 372 17. Kirtane, K., et al., "I have cancer during COVID; that's a special category": a qualitative study 373 of head and neck cancer patient and provider experiences during the COVID-19 pandemic. 374 Support Care Cancer, 2022. 30(5): p. 4337-44.
- 375 18. Rodrigues-Oliveira, L., et al., COVID-19 impact on anxiety and depression in head and neck 376 cancer patients: A cross-sectional study. Oral Dis, 2021.
- 377 19. Büntzel, J., et al., Oncology Services for Patients with Head Neck Cancer during Corona-Times 378 - Patients' Perspective. Laryngorhinootologie, 2021. 100(2): p. 104-10.
- 379 20. Verdonck-de Leeuw, I.M., et al., Advancing interdisciplinary research in head and neck cancer 380 through a multicenter longitudinal prospective cohort study: the NETherlands QUality of life 381 and Blomedical Cohort (NET-QUBIC) data warehouse and biobank. BMC Cancer, 2019. 19(1): p. 382 765.
- 383 21. Jansen, F., et al., Study retention and attrition in a longitudinal cohort study including 384 patient-reported outcomes, fieldwork and biobank samples: results of the Netherlands quality 385 of life and Biomedical cohort study (NET-QUBIC) among 739 head and neck cancer patients and 386 262 informal caregivers. BMC Med Res Methodol, 2022. 22(1): p. 27.
- 387 22. von Elm, E., et al., Strengthening the Reporting of Observational Studies in Epidemiology 388 (STROBE) statement: guidelines for reporting observational studies. BMJ, 2007. 335(7624): p. 389 806-8.

- 390 23. Aaronson, N.K., et al., The European Organization for Research and Treatment of Cancer QLQ 391 C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. JNCI:
   392 Journal of the National Cancer Institute, 1993. 85(5): p. 365-76.
- 393 24. Fayers, P. and A. Bottomley, *Quality of life research within the EORTC the EORTC QLQ-C30.* 394 European Journal of Cancer, 2002. 38(4): p. 125-33.
- 395 25. Giesinger, J.M., et al., *Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust.* J Clin Epidemiol, 2016. 69: p. 79-88.
- 397 26. Bjordal, K., et al., Development of a European Organization for Research and Treatment of
   398 Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and
   399 neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol, 1994. 33(8): p. 879-85.
- 400 27. Schuit, A.J., et al., *Validity of the Physical Activity Scale for the Elderly (PASE): according to*401 *energy expenditure assessed by the doubly labeled water method.* J Clin Epidemiol, 1997.
  402 50(5): p. 541-46.
- 403 28. Washburn, R.A., et al., *The physical activity scale for the elderly (PASE): evidence for validity.*404 J Clin Epidemiol, 1999. 52(7): p. 643-51.
- 405 29. Spinhoven, P., et al., A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med, 1997. 27(2): p. 363-70.
- 30. Custers, J.A., et al., *The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors.* Cancer Nurs, 2014. 37(1): p. E44-50.
- 409 31. de Jong-Gierveld, J., *Developing and testing a model of Ioneliness.* J Pers Soc Psychol, 1987. 410 53(1): p. 119-28.
- 411 32. de Jong-Gierveld, J. and F. Kamphuis, *The development of a Rasch-type Ioneliness scale.* Appl 412 Physiol Maes, 1985. 9(3): p. 289-99.
- 413 33. de Jong-Gierveld, J. and T.G. van Tilburg. *Manual of the Loneliness Scale*. 2022 24-02-2022 414 [cited 2022 06-09-2022].
- 34. Hoekstra, H.A., J. Ormel, and F. de Fruyt, EO-PI-R en NEO-FFI: Big Five
   Persoonlijkheidsvragenlijsten: Handleiding. 1996, Lisse: Swets & Zeitlinger.
- 417 35. Paleri, V. and R.G. Wight, Applicability of the adult comorbidity evaluation-27 and the
  418 Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom
  419 patients with head and neck cancer: A retrospective study. J Laryngol Otol, 2002. 116(3): p.
  420 200-5.
- 421 36. Lawton, M.P., *Scales to measure competence in everyday activities.* Psychopharmacol Bull, 1988. 24(4): p. 609-14.
- 423 37. Wittchen, H.-U., *Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): A critical review.* J Psychiatr Res, 1994. 28(1).
- 38. Kanatas, A., et al., Follow-up arrangements in head and neck cancer clinics during the COVID-19 pandemic: results from two tertiary UK head and neck cancer centres. Ann R Coll Surg Engl. [Online ahead of print].
- 428 39. Dermody, S.M. and A.G. Shuman, *Psychosocial Implications of COVID-19 on Head and Neck* 429 *Cancer.* Curr Oncol, 2022. 29(2): p. 1062-8.
- 430 40. Surujballi, J., et al., *The COVID-19 pandemic: An opportunity to rethink and harmonise the*431 *frequency of follow-up visits for patients with early stage breast cancer.* Cancer Treat Rev,
  432 2021. 97: p. 102188.
- 43. Kazazian, K., D. Ng, and C.J. Swallow, *Impact of the coronavirus disease 2019 pandemic on delivery of and models for supportive and palliative care for oncology patients.* Curr Opin Support Palliat Care, 2022. 16(3): p. 130-137.
- 42. Hatton, R.A., et al., A survey to ascertain peer support models available in Head and Neck cancer across the United Kingdom. Br J Oral Maxillofac Surg, 2022. 60(4): p. 488-492.
- 43. Tian, Y., et al., Cancer associates with risk and severe events of COVID-19: A systematic review and meta-analysis. Int J Cancer, 2021. 148(2): p. 363-374.

## **Tables and Figures**

441

442

Table 1. Patients characteristics at baseline unless specified otherwise. Data is described as number and percentage or as mean (standard deviation).

	before C	M36 asse OVID-19	during C	OVID-19	p-value
	(N=1	199)	(N=1		
Age (years)	63.5	(9.6)	63.6	0.89	
Gender					0.091
Men	140	70.4%	94	79.0%	
Women	59	29.6%	25	21.0%	
Education level					0.33
Low	82	43.4%	41	35.3%	
Middle	50	26.5%	32	27.6%	
High	57	30.2%	43	37.1%	
Missing	10		3		0.044
Living arrangement	455	00 40/	0.4	<b>-2</b> -0/	0.044
Living together	157	83.1%	86	73.5%	
Living alone	32	16.9%	31	26.5%	
Missing Marital status	10		2		0.33
Not married	62	32.8%	45	38.5%	0.33
Married	127	67.2%	72		
Missing	1 <b>27</b> 10	67.2%	2	61.5%	
NEO-FFI extraversion <sup>a</sup>	41.2	(6.1)	40.3	(6.5)	0.23
Tumor location		(31.)	10.5	(0.5)	0.69
Oral cavity	50	25.1%	30	25.2%	0.07
Oropharynx	72	36.2%	43	36.1%	
Hypopharynx	14	7.0%	4	3.4%	
Larynx	57	28.6%	37	31.1%	
Unknown primary	6	3.0%	5	4.2%	
Tumor stage	Ŭ	3.070	•	1.2/0	0.19
Stage O(Cis)/I*	52	26.1%	32	26.9%	0.17
Stage II	35	17.6%	24	20.2%	
Stage III	38	19.1%	12	10.1%	
Stage IV	74	37.2%	51	42.9%	
Treatment modality (dichotomized)	, .	37.270	3.	12.770	0.56
Single modality	114	57.3%	64	53.8%	0.30
Multimodality	85	42.7%	55	46.2%	
WHO performance status	03	72.770	33	40.2/0	0.59
0	152	76.4%	94	79.0%	0.57
>0	47	23.6%	25	21.0%	
Comorbidity	77	23.0%	23	21.070	0.55
None	68	34.7%	48	40.7%	0.33
Mild	76	38.8%	46	39.0%	
Moderate	36	18.4%	18	15.3%	
Severe	16	8.2%	6	5.1%	
Missing	3	0.2/0	1	3.170	
Cancer progression status at M24					0.98
Disease free	165	82.9%	98	83.1%	
Residual, recurrence and/or SP	34	17.1%	20	16.9%	
Residual	5	2.5%	3	2.5%	
Recurrence	18	9.0%	12	10.2%	
Second primary	12	6.0%	7	5.9%	
Missing			1		
Type tumor recurrence					
Local recurrence (< 2 cm and <3 year)	6	33.3%	3	25.0%	
Regional recurrence	3	16.7%	3	25.0%	

Distant metastasis	3	16.7%	1	8.3%	
Delayed lymph node metastasis	6	33.3%	5	41.7%	
Treatment intent (in case of residual,					
recurrence and/or SP) at M24					
Curative intent	30	15.1%	19	16.1%	
Palliative intent	4	2.0%	1	0.8%	
	=		•		0.22
IADL at M24 <sup>b</sup>	7.3 (1.0)		7.2 (	1.0)	0.33
Major depressive disorder past year at M24		<b>a-</b>			0.54
No	172	95.6%	109	97.3%	
Yes	8	4.4%	3	2.7%	
Missing	19		7		
Lifetime major depressive disorder at M24					0.24
No	124	82.1%	69	75.8%	
Yes	27	17.9%	22	24.2%	
Missing	48		28		
Paid work at M24					0.94
No	134	70.5%	83	70.9%	
Yes	56	29.5%	34	29.1%	
Missing	9		2		
Excessive alcohol consumption at M24					0.38
No	163	88.1%	95	84.1%	
Yes	22	11.9%	18	15.9%	
Missing	14		6		
Smoking behavior at M24					0.79
Not a current smoker	162	87.1%	97	88.2%	
Current smoker	24	12.9%	13	11.8%	
Missing	13		9		
BMI (kg/m2) at M24 <sup>b</sup>	25.8	(4.2)	26.2	(4.1)	0.42

<sup>\*</sup>One patient had a cTNM stage of 0, however, pTNM was stage 2.

\*missing for n=8 before COVID and n=7 during COVID

bmissing for n=19 before COVID and n=7 during COVID

SP=second primary; NEO-FFI= NEO Five Factor Inventory; IADL= deze Instrumental Activities of Daily Living; BMI=body

Table 2. Estimated effect sizes (estimated differences for continuous PROMs or odds ratios for dichotomous and categorical PROMs) with corresponding 95% confidence intervals and p-values of the two-way interactions time by group, to assess differences between groups in change of PROMs between 24 and 36 months follow-up.


PROM	p-value	ES	95% CI
EORTC - C30 domain	p 14.40		70.00.
Global quality of life [0-100]	0.44	1.4	[-2.2; 4.9]
Physical functioning [0-100]	0.15	1.5	[-0.58; 3.6]
Role functioning [0-100]	0.22	2.7	[-1.6; 7.0]
Emotional functioning [0-100]	0.19	2.2	[-1.1; 5.5]
Cognitive functioning [0-100]	0.52	-1.1	[-4.4; 2.2]
Social functioning [0-100]	0.17	2.8	[-1.2; 6.9]
Fatigue [0-100]	0.21	2.4	[-1.4; 6.2]
Nausea Vomiting [0-100]	0.29	-0.97	[-2.8; 0.84]
Pain [0-100]	0.29	-2.0	[-5.6; 1.7]
Dyspnoe [0-100]	0.80	0.52	[-3.6; 4.6]
Insomnia [0-100]	0.44	2.0	[-3.2; 7.2]
Loss of appetite [0-100]	0.018	-4.4	[-8.1; -0.75]
Constipation [0-100]	0.76	-0.53	[-3.9; 2.9]
Diarrhoea [0-100]	0.65	-0.75	[-4.0; 2.5]
Financial problems [0-100]	0.15	2.5	
EORTC summary score [0-100]	0.14	1.2	[-0.41; 2.8]
EORTC - HN35 domain			
Pain [0-100]	0.65	-0.73	[-3.8; 2.4]
Swallowing [0-100]	0.24	-1.5	[-4.1; 1.0]
Senses problems [0-100]	0.62	-0.91	[-4.5; 2.6]
Trouble with social contact [0-100]	0.71	-0.42	[-2.6; 1.8]
Trouble with social eating [0-100]	0.70	-0.50	[-3.1; 2.1]
Speech problems [0-100]	0.26	1.7	[-1.3; 4.6]
Less sexuality [0-100]	0.96	-0.19	[-7.0; 6.6]
Teeth [0-100]	0.40	2.2	[-3.0; 7.5]
Opening mouth [0-100]	0.23	2.3	[-1.5; 6.0]
Dry mouth [0-100]	0.20	-3.1	[-7.8; 1.7]
Sticky saliva [0-100]	0.47	1.9	[-3.4; 7.3]
Coughing [0-100]	0.45	2.1	[-3.4; 7.7]
Felt ill [0-100]	0.82	0.57	[-4.2; 5.4]
Painkillers (dichotomous)	0.89	1.04	[0.62; 1.8]
Nutritional supplements (dichotomous)	0.93	1.03	[0.51; 2.1]
Feeding tube (dichotomous)	n.e.	0.44	[0 44, 4 9]
Weight loss (dichotomous)	0.26 0.28	0.44	[0.11; 1.8]
Weight gain (dichotomous) PASE	0.28	1.5	[0.72; 3.1]
Leisure activity	0.064	9.3	[-0.54; 19.1]
Household activity	0.004	7.2	[-9.1; 23.4]
Work activity	0.39	3.8	[-6.3; 14.0]
Total activity	0.43	20.2	
Total activity  Total activity (categorical)	0.10	0.78	[0.52; 1.2]
HADS	0.24	0.70	[0.32, 1.2]
Depression [0-21]	0.61	-0.16	[-0.75; 0.44]
Anxiety [0-21]	0.53	0.16	
Total score [0-42]	0.79	0.12	[-0.78; 1.0]
CWS	0.,,	0	[ 0.70, 1.0]
Fear of recurrence [8-32]	0.46	-0.26	[-0.95; 0.43]
De Jong Gierveld	33	3.23	[ 0.70, 05]
Emotional loneliness score [0-6]	0.52	-0.11	[-0.44; 0.22]
Social loneliness score [0-5]	0.27	0.19	•
Total loneliness score [0-11]	0.69	0.10	[-0.41; 0.62]
			_ · · , - · · - ]

Total loneliness score (categorical)	0.49	1.2	[0.75; 1.8]

n.e.=not estimable due to low number of events


449


## Figure 1. Flow diagram of NET-QUBIC patients included in the current study.



HNC=head and neck cancer; M24=24 months follow-up assessment; M36=36 months follow-up assessment; PROM=patient reported outcome measure; T0=baseline assessment

Figure 2. Estimated effect sizes (estimated differences for continuous PROMs or odds ratios for dichotomous and categorical PROMs) with corresponding 95% confidence intervals and p-values for the differences between groups in change of PROMs between 24 and 36 months follow-up, overall and stratified by influencing factor. A) continuous PROMs. B) dichotomous and categorical PROMs.





## **Supplementary Tables**

Supplemental Table 1. Patients characteristics at baseline unless specified otherwise for included survivors compared to excluded survivors. Data is described as number and percentage or as mean (standard deviation).

	included study (N		excluded study (N	p-value	
Age (years)	63.5 (		63.3 (		0.77
Gender	`	,	`	,	0.94
Men	234	73.6%	105	<b>73.9</b> %	
Women	84	26.4%	37	26.1%	
Education level					0.77
Low	123	40.3%	58	43.0%	
Middle	82	26.9%	32	23.7%	
High	100	32.8%	45	33.3%	
Missing	13		7		
Living arrangement					0.70
Living together	243	79.4%	105	77.8%	
Living alone	63	20.6%	30	22.2%	
Missing	12		7		
Marital status		2= 20/		• • • • • • • • • • • • • • • • • • • •	0.75
not married	107	35.0%	49	36.6%	
married	199	65.0%	85	63.4%	
Missing	12	( 3)	8	(* 4)	0.47
NEO-FFI extraversion <sup>a</sup>	40.9 (	6.3)	39.9 (	(6.1)	0.17
Tumor location	00	25 20/	40	20.20/	0.53
Oral cavity	80	25.2%	40	28.2%	
Oropharynx	115	36.2%	48	33.8%	
Hypopharynx	18	5.7%	4	2.8%	
Larynx	94	29.6%	47 3	33.1%	
Unknown primary	11	3.5%	3	2.1%	0.56
Tumor stage Stage 0(Cis)/I*	84	26.4%	38	26.8%	0.36
Stage II	59	18.6%	33	23.2%	
Stage III	50	15.7%	17	12.0%	
Stage IV	125	39.3%	54	38.0%	
Treatment modality (dichotomized)	123	37.3/0	34	30.070	0.44
Single modality	178	56.0%	85	59.9%	0.11
Multimodality	140	44.0%	57	40.1%	
WHO performance status	1 10	11.070	3,	10.170	
0	246	77.4%	102	71.8%	0.20
>0	72	22.6%	40	28.2%	0.20
Comorbidity					0.010
None	116	36.9%	30	23.1%	0.0.0
Mild	122	38.9%	52	40.0%	
Moderate	54	17.2%	31	23.8%	
Severe	22	7.0%	17	13.1%	
Missing	4		12		
IADL at M24 <sup>b</sup>	7.2 (1	1.0)	7.1 ( <sup>-</sup>	1.2)	0.25
Major depressive disorder past year at M24	`	,	`	,	0.013
No	245	95.3%	98	89.9%	
Yes	12	4.7%	11	10.1%	
Missing	61		33		
Lifetime major depressive disorder at M24					0.005
No	225	87.5%	66	65.3%	
Yes	32	12.5%	35	34.7%	
Missing	61		41		

Paid work at M24					0.039
No	192	65.1%	82	<b>75.9</b> %	
Yes	103	34.9%	26	24.1%	
Missing	23		34		
Excessive alcohol consumption at M24					0.37
No	228	78.9%	51	82.3%	
Yes	61	21.1%	11	17.7%	
Missing	29		80		
Smoking behavior at M24					0.19
Not a current smoker	239	82.7%	52	81.3%	
Current smoker	50	17.3%	12	18.8%	
Missing	29		78		
BMI (kg/m2) at M24 <sup>b</sup>	26.2 (·	4.3)	25.1 (	4.3)	0.074

<sup>\*</sup>One patient had a cTNM stage of 0, however, pTNM was stage 2.
amissing for n=32 excluded and n=15 included

bmissing for n=34 excluded and n=26 included
NEO-FFI=NEO Five Factor Inventory; IADL=deze Instrumental Activities of Daily Living; BMI=body mass index

Supplemental Table 2. Descriptive statistics (total sample size (N), mean and standard deviation (SD)) per measurement for continuous PROMs per group.

		M36 I	before CO\	/ID (N=19	9)			M36 (	during COV	/ID (N=11	119)		
_		M24			M36			M24			M36		
PROM	N	mean	SD	N	mean	SD	N	mean	SD	N	mean	SD	
EORTC - C30 domain													
Global quality of life [0-100]	189	79.7	17.0	192	81.1	15.8	118	79.7	17.0	108	79.2	18.8	
Physical functioning [0-100]	189	87.7	14.4	193	87.7	16.3	118	89.3	14.8	110	87.8	17.6	
Role functioning [0-100]	189	86.7	21.3	193	87.7	22.2	118	88.6	20.1	110	87.0	22.4	
Emotional functioning [0-100]	189	89.0	16.7	193	89.6	15.9	118	90.8	14.3	108	89.1	15.6	
Cognitive functioning [0-100]	189	89.7	15.5	193	88.9	16.0	118	87.6	16.0	108	87.8	15.9	
Social functioning [0-100]	189	91.5	15.9	193	91.5	16.1	118	93.5	13.1	108	90.6	19.2	
Fatigue [0-100]	189	20.1	20.6	192	21.5	22.6	118	21.7	21.3	110	21.4	22.0	
Nausea Vomiting [0-100]	189	1.5	5.6	193	1.6	7.0	118	0.8	5.3	110	1.8	6.1	
Pain [0-100]	189	13.1	19.1	193	11.6	18.5	118	12.0	20.2	110	12.9	20.9	
Dyspnoe [0-100]	189	12.2	22.5	193	14.2	23.7	118	12.1	21.6	110	13.9	24.9	
Insomnia [0-100]	189	16.0	24.7	192	17.0	25.7	118	20.1	26.6	110	19.4	28.0	
Loss of appetite [0-100]	189	7.6	17.1	193	5.7	15.5	118	4.8	15.9	110	7.3	20.9	
Constipation [0-100]	189	6.5	15.7	193	6.7	16.5	117	6.3	14.5	110	6.7	14.8	
Diarrhoea [0-100]	189	6.0	15.0	191	4.2	13.9	117	4.3	12.0	110	3.3	10.0	
Financial problems [0-100]	187	5.2	15.6	193	6.4	15.9	118	5.9	18.3	108	4.9	16.3	
EORTC summary score [0-100]	189	89.4	9.9	190	89.7	10.3	117	89.9	10.0	108	88.8	12.1	
EORTC - HN35 domain													
Pain [0-100]	188	12.0	15.8	193	10.2	14.1	117	10.6	15.2	108	9.4	16.3	
Swallowing [0-100]	189	9.7	14.6	193	9.3	13.6	118	7.8	14.1	108	9.1	16.4	
Senses problems [0-100]	189	12.6	19.9	193	13.2	21.3	118	11.7	19.6	108	13.0	23.7	
Trouble with social contact [0-100]	189	2.2	7.0	193	3.4	10.4	117	3.0	8.0	108	4.4	9.9	
Trouble with social eating [0-100]	189	8.2	15.7	193	8.9	17.6	118	5.6	12.2	108	7.2	17.7	
Speech problems [0-100]	189	9.9	14.7	193	10.4	15.5	118	9.7	14.6	108	8.5	15.5	
Less sexuality [0-100]	176	23.7	32.1	177	27.6	34.5	108	23.8	31.5	102	28.4	32.5	
Teeth [0-100]	189	10.8	21.9	193	11.7	22.6	117	8.5	18.1	107	7.5	17.3	
Opening mouth [0-100]	189	8.5	21.7	193	10.0	21.6	118	9.6	22.7	108	8.6	17.9	
Dry mouth [0-100]	188	35.5	32.8	193	33.2	30.3	118	28.5	28.7	108	29.3	26.9	
Sticky saliva [0-100]	188	24.8	28.0	188	24.8	28.0	118	21.2	30.7	108	20.7	27.2	
Coughing [0-100]	189	19.6	24.0	193	19.2	24.4	118	18.9	24.5	108	16.4	22.1	
Felt ill [0-100]	189	7.4	17.6	193	6.6	15.7	118	5.4	13.8	108	4.0	11.8	
PASE													
Leisure activity	187	40.7	40.2	188	42.3	36.7	115	49.5	54.6	110	42.3	43.1	

Household activity	187	71.6	59.7	188	79.6	79.5	115	69.9	64.6	110	70.4	62.3
Work activity	186	18.3	39.8	184	20.7	43.0	112	14.2	32.7	108	11.9	35.5
Total activity	187	130.5	93.5	188	142.1	104.6	115	133.2	106.4	110	124.4	96.1
HADS												
Depression [0-21]	187	2.5	2.9	188	2.5	3.2	118	2.6	3.2	110	2.9	3.3
Anxiety [0-21]	188	3.0	3.1	189	3.0	3.2	118	3.0	3.1	108	2.8	2.9
Total score [0-42]	186	5.5	5.4	187	5.5	5.7	118	5.6	5.9	108	5.6	5.4
CWS												
Fear of recurrence [8-32]	184	11.8	4.0	187	11.6	3.5	114	11.5	3.4	108	11.4	4.2
De Jong Gierveld												
Emotional loneliness score [0-6]	180	1.0	1.6	185	1.1	1.8	112	1.1	1.8	109	1.3	1.9
Social loneliness score [0-5]	184	1.4	1.7	185	1.6	1.8	113	1.5	1.8	107	1.5	1.7
Total loneliness score [0-11]	184	2.4	3.0	186	2.7	3.1	114	2.6	3.2	109	2.7	3.1

Supplemental Table 3. Descriptive statistics (frequency (n) and percentage) per assessment for dichotomous and categorical PROMs per group.

		perore co	VID (N=199	")	M36 during COVID (N=119)			
	M24	1	M36		M24		M36	5
·	n	%	n	%	n	%	n	%
no	135	71.8%	140	72.9%	84	71.8%	81	73.6%
yes	53	28.2%	52	27.1%	33	28.2%	29	26.4%
no	170	90.4%	173	89.6%	106	91.4%	100	90.9%
yes	18	9.6%	20	10.4%	10	8.6%	10	9.1%
no	188	99.5%	191	99.0%	116	100.0%	109	99.1%
yes	1	0.5%	2	1.0%	0	0.0%	1	0.9%
no	178	94.7%	179	92.7%	113	96.6%	99	90.0%
yes	10	5.3%	14	7.3%	4	3.4%	11	10.0%
no	148	79.6%	157	82.2%	94	81.7%	95	88.8%
yes	38	20.4%	34	17.8%	21	18.3%	12	11.2%
•								
very poor	26	13.9%	33	17.6%	25	21.7%	30	27.3%
poor	59	31.6%	43	22.9%	27	23.5%	24	21.8%
fair	41	21.9%	39	20.7%	25	21.7%	17	15.5%
good	24	12.8%	34	18.1%	16	13.9%	17	15.5%
_	18	9.6%	15	8.0%	8	7.0%	12	10.9%
	19		24				10	9.1%
not lonely [0-2]	117	63.6%	117	62.9%	74	64.9%	65	59.6%
								32.1%
								7.3%
							1	0.9%
	yes no yes no yes no yes no yes very poor	no 135 yes 53 no 170 yes 18 no 188 yes 1 no 178 yes 10 no 178 yes 30 very poor 26 poor 59 fair 41 good 24 very good 18 excelent 19 not lonely [0-2] 117 moderate [3-8] 55 severe [9-10] 10	no 135 71.8% yes 53 28.2% no 170 90.4% yes 18 9.6% no 188 99.5% yes 1 0.5% no 178 94.7% yes 10 5.3% no 148 79.6% yes 38 20.4% very poor 26 13.9% poor 59 31.6% fair 41 21.9% good 24 12.8% very good 18 9.6% excelent 19 10.2% not lonely [0-2] 117 63.6% moderate [3-8] 55 29.9% severe [9-10] 10 5.4%	no 135 71.8% 140 yes 53 28.2% 52 no 170 90.4% 173 yes 18 9.6% 20 no 188 99.5% 191 yes 1 0.5% 2 no 178 94.7% 179 yes 10 5.3% 14 no 148 79.6% 157 yes 38 20.4% 34 very poor 59 31.6% 43 fair 41 21.9% 39 good 24 12.8% 34 very good 18 9.6% 15 excelent 19 10.2% 24 not lonely [0-2] 117 63.6% 117 moderate [3-8] 55 29.9% 52 severe [9-10] 10 5.4% 15	no 135 71.8% 140 72.9% yes 53 28.2% 52 27.1% no 170 90.4% 173 89.6% yes 18 9.6% 20 10.4% no 188 99.5% 191 99.0% yes 1 0.5% 2 1.0% no 178 94.7% 179 92.7% yes 10 5.3% 14 7.3% no 148 79.6% 157 82.2% yes 38 20.4% 34 17.8% very poor 26 13.9% 33 17.6% poor 59 31.6% 43 22.9% fair 41 21.9% 39 20.7% good 24 12.8% 34 18.1% very good 18 9.6% 15 8.0% excelent 19 10.2% 24 12.8% not lonely [0-2] 117 63.6% 117 62.9% moderate [3-8] 55 29.9% 52 28.0% severe [9-10] 10 5.4% 15 8.1%	no 135 71.8% 140 72.9% 84 yes 53 28.2% 52 27.1% 33 no 170 90.4% 173 89.6% 106 yes 18 9.6% 20 10.4% 10 no 188 99.5% 191 99.0% 116 yes 1 0.5% 2 1.0% 0 no 178 94.7% 179 92.7% 113 yes 10 5.3% 14 7.3% 4 no 148 79.6% 157 82.2% 94 yes 38 20.4% 34 17.8% 21 very poor 59 31.6% 43 22.9% 27 fair 41 21.9% 39 20.7% 25 good 24 12.8% 34 18.1% 16 very good 18 9.6% 15 8.0% 8 excelent 19 10.2% 24 12.8% 14 not lonely [0-2] 117 63.6% 117 62.9% 74 moderate [3-8] 55 29.9% 52 28.0% 33 severe [9-10] 10 5.4% 15 8.1% 2	no	no       135       71.8%       140       72.9%       84       71.8%       81         yes       53       28.2%       52       27.1%       33       28.2%       29         no       170       90.4%       173       89.6%       106       91.4%       100         yes       18       9.6%       20       10.4%       10       8.6%       10         no       188       99.5%       191       99.0%       116       100.0%       109         yes       1       0.5%       2       1.0%       0       0.0%       1         no       178       94.7%       179       92.7%       113       96.6%       99         yes       10       5.3%       14       7.3%       4       3.4%       11         no       148       79.6%       157       82.2%       94       81.7%       95         yes       38       20.4%       34       17.8%       21       18.3%       12         very poor       26       13.9%       33       17.6%       25       21.7%       30         poor       59       31.6%       43       22.9%       27

Supplemental Table 4. P-values for the three-way interaction between time, group and each potential influencing factor, to identify potential modifiers of the effect on the change of PROMs between 24 months and 36 months follow-up. Factors as assessed at baseline unless specified otherwise

onal Living arrangement 0.71 0.49	• •	extraversion
	0.34	0.62
0.30	0.05	0.24
0.88	0.44	0.11
		0.27
		0.38
		0.99
		0.091
0.73		0.75
		0.96
	0.29	0.46
0.77	0.89	0.71
	0.92	0.53
0.028	0.11	0.31
	0.39	0.88
		0.31
0.72	0.63	0.16
		0.80
		0.098
		0.73
		0.25
		0.21
		0.70
		0.92
		0.87
0.45	0.64	0.74
0.75	0.72	0.20
0.97	0.45	0.57
0.005	0.040	0.23
	0.61	0.07
	0.015	0.92
0.30 0.37	0.63	0.44
	0.59       0.30         0.88       0.88         0.44       0.52         0.73       0.94         0.29       0.54         0.45       0.99         0.22       0.73         0.74       0.69         0.92       0.69         0.85       0.77         0.25       0.12         0.59       0.028         0.37       0.84         0.23       0.60         0.72       0.72         0.53       0.18         0.83       0.55         0.91       0.093         0.11       0.020         0.94       0.51         0.59       0.38         0.13       0.39         0.13       0.39         0.14       0.05         0.29       0.97         0.65       0.75         0.65       0.75         0.61       0.005         0.92       0.83         0.67       0.004	0.59       0.30       0.05         0.88       0.88       0.44         0.44       0.52       0.85         0.73       0.94       0.96         0.29       0.54       0.70         0.45       0.99       0.94         0.22       0.73       0.82         0.74       0.69       0.35         0.92       0.69       0.29         0.85       0.77       0.89         0.25       0.12       0.92         0.59       0.028       0.11         0.37       0.84       0.39         0.23       0.60       0.41         0.72       0.72       0.63         0.53       0.18       0.78         0.83       0.55       0.42         0.91       0.093       0.05         0.11       0.020       0.037         0.11       0.020       0.037         0.12       0.92       0.38         0.79       0.14         0.59       0.45       0.64         0.65       0.75       0.72         0.61       0.005       0.040         0.92       0.83       0.61

Feeding tube	n.e.	n.e.	n.e.	n.e.	n.e.	n.e.
Weight loss	0.67	n.e.	< 0.001	n.e.	0.77	1.00
Weight gain	0.17	0.91	0.34	0.33	0.82	0.19
PASE						
Leisure activity	0.48	0.13	0.54	0.37	0.19	0.24
Household activity	0.87	0.08	0.21	0.56	0.36	0.16
Work activity	0.60	0.43	0.39	0.68	0.37	0.80
Total activity	0.85	0.033	0.20	0.36	0.14	0.70
Total activity (categorical)	0.15	0.018	0.34	0.55	0.11	0.99
HADS						
Depression [0-21]	0.022	0.094	0.58	0.35	0.15	0.80
Anxiety [0-21]	0.10	0.021	0.30	0.42	0.19	0.27
Total score [0-42]	0.023	0.070	0.43	0.34	0.12	0.43
CWS						
Fear of recurrence [8-32]	0.09	0.67	0.045	0.96	0.88	0.85
De Jong Gierveld						
Emotional loneliness score [0-6]	0.82	0.92	0.33	0.72	0.49	0.61
Social loneliness score [0-5]	0.26	0.61	0.57	0.56	0.09	0.78
Total loneliness score [0-11]	0.24	0.88	0.25	0.96	0.67	0.70
Total loneliness score (categorical)	0.18	0.82	0.16	0.96	0.36	0.89

n.e.=not estimable due to low number of events

						Cancer
	_	_			WHO	progression
PP-014	Tumor	Tumor	Treatment		performance	status
PROM	location	stage	modality	Comorbidity	status	(M24)
EORTC - C30 domain						
Global quality of life [0-100]	0.15	0.43	0.84	0.84	0.73	0.41
Physical functioning [0-100]	0.31	0.96	0.88	0.19	0.56	0.78
Role functioning [0-100]	0.54	0.015	0.51	0.09	0.36	0.20
Emotional functioning [0-100]	0.66	0.21	0.14	0.73	0.57	0.028
Cognitive functioning [0-100]	0.051	0.87	0.31	0.030	0.87	0.35
Social functioning [0-100]	0.27	0.82	0.62	0.095	0.73	0.22
Fatigue [0-100]	0.69	0.42	0.26	0.58	0.56	0.24
Nausea Vomiting [0-100]	0.23	0.99	0.89	0.39	0.18	0.43
Pain [0-100]	0.89	0.94	0.88	0.14	0.59	0.78
Dyspnoe [0-100]	0.76	0.57	0.73	0.22	0.80	0.09
Insomnia [0-100]	0.61	0.28	0.96	0.70	0.94	0.15
Loss of appetite [0-100]	0.048	0.60	0.046	0.003	0.75	0.63
Constipation [0-100]	0.86	0.07	0.26	0.19	0.79	0.22
Diarrhoea [0-100]	0.098	0.09	0.077	0.74	0.26	1.00
Financial problems [0-100]	0.69	0.40	0.60	0.21	0.004	0.001
EORTC summary score [0-100]	0.21	0.13	0.38	0.18	0.90	0.95
EORTC - HN35 domain						
Pain [0-100]	0.017	0.32	0.78	0.23	0.87	0.015
Swallowing [0-100]	0.69	0.96	0.90	< 0.001	0.020	0.010
Senses problems [0-100]	0.92	0.07	0.13	0.066	0.089	0.034
Trouble with social contact [0-100]	0.22	0.74	0.29	0.33	0.52	0.29
Trouble with social eating [0-100]	0.94	0.74	0.62	0.039	0.89	0.14
Speech problems [0-100]	0.15	0.42	0.20	0.95	0.92	0.93
Less sexuality [0-100]	0.88	0.63	0.47	0.026	0.48	0.31
Teeth [0-100]	0.53	1.00	0.85	0.083	0.22	0.18
Opening mouth [0-100]	0.091	0.30	0.90	0.76	0.38	0.74
Dry mouth [0-100]	0.007	0.78	0.69	0.37	0.52	0.25
Sticky saliva [0-100]	0.48	0.56	0.75	0.35	0.82	0.035
Coughing [0-100]	0.12	0.17	0.34	0.085	0.64	0.56
Felt ill [0-100]	0.42	0.30	0.58	0.15	0.13	0.63
Painkillers	0.14	0.40	0.17	0.13	0.14	0.32

Nutritional supplements	n.e.	0.42	0.31	<0.001	0.55	0.66
Feeding tube	n.e.	n.e.	n.e.	n.e.	n.e.	n.e.
Weight loss	0.77	< 0.001	0.23	< 0.001	0.69	0.60
Weight gain	1.00	0.78	0.73	0.57	0.21	0.35
PASE						
Leisure activity	0.63	0.007	0.36	0.98	0.46	0.82
Household activity	0.07	0.97	0.49	0.94	0.06	0.44
Work activity	1.00	0.83	0.44	0.61	0.58	0.50
Total activity	0.22	0.33	0.88	0.94	0.19	0.85
Total activity (categorical)	0.003	0.48	0.81	0.27	0.07	0.90
HADS						
Depression [0-21]	0.77	0.76	0.022	0.35	0.74	0.64
Anxiety [0-21]	0.53	0.55	0.51	0.46	0.99	0.42
Total score [0-42]	0.64	0.99	0.035	0.55	0.77	0.39
CWS						
Fear of recurrence [8-32]	0.65	0.051	0.30	0.51	0.14	0.64
De Jong Gierveld						
Emotional loneliness score [0-6]	0.48	0.24	0.023	0.54	0.83	0.045
Social loneliness score [0-5]	0.36	0.25	0.65	0.79	0.22	0.63
Total loneliness score [0-11]	0.43	0.08	0.09	0.50	0.44	0.10
Total loneliness score (categorical)	0.30	0.64	0.65	0.39	0.92	0.20

n.e.=not estimable due to low number of events

PROM	IADL (M24)	Major depressive disorder past year (M24)	Lifetime major depresssive disorder (M24)	Paid work (M24)	Excessive alcohol consumption (M24)	Smoking behavior (M24)	BMI (M24)
EORTC - C30 domain							
Global quality of life [0-100]	0.93	0.57	0.30	0.49	0.61	0.21	0.66
Physical functioning [0-100]	0.56	0.29	0.20	0.24	0.66	0.71	0.37
Role functioning [0-100]	1.00	0.014	0.24	0.42	0.47	0.015	0.30
Emotional functioning [0-100]	0.069	0.61	0.63	0.80	0.72	0.090	0.56
Cognitive functioning [0-100]	0.84	0.28	0.40	0.46	0.71	0.11	0.12
Social functioning [0-100]	0.88	0.10	0.55	0.19	0.69	0.47	0.92
Fatigue [0-100]	0.053	0.73	0.91	0.09	0.35	0.41	0.20
Nausea Vomiting [0-100]	0.95	0.40	0.37	0.15	0.26	0.13	0.74
Pain [0-100]	0.66	0.92	0.81	0.74	0.51	0.91	0.44
Dyspnoe [0-100]	0.24	0.95	0.84	0.79	0.60	0.15	0.20
Insomnia [0-100]	0.065	0.82	0.80	0.66	0.20	0.46	0.36
Loss of appetite [0-100]	0.68	0.99	0.30	0.35	0.34	0.79	0.19
Constipation [0-100]	0.88	0.35	0.32	0.71	0.28	0.62	0.26
Diarrhoea [0-100]	0.078	0.89	0.10	0.020	0.69	0.16	0.53
Financial problems [0-100]	0.008	0.64	0.84	0.21	0.64	0.69	0.23
EORTC summary score [0-100]	0.97	0.96	0.11	0.60	0.44	0.99	0.81
EORTC - HN35 domain							
Pain [0-100]	0.90	0.16	0.81	0.57	0.73	0.68	0.020
Swallowing [0-100]	0.32	0.63	0.11	0.72	0.74	0.60	0.58
Senses problems [0-100]	0.37	0.78	0.78	0.47	0.13	0.89	0.30
Trouble with social contact [0-100]	0.99	0.001	0.027	0.056	1.00	0.003	0.25
Trouble with social eating [0-100]	0.39	0.20	0.42	0.41	0.23	0.30	0.18
Speech problems [0-100]	0.90	0.78	0.90	0.64	0.43	0.86	0.39
Less sexuality [0-100]	0.36	0.19	0.023	0.76	0.30	0.83	0.16
Teeth [0-100]	0.63	0.84	0.84	0.34	0.97	0.52	0.19
Opening mouth [0-100]	0.65	0.29	0.011	0.36	0.49	0.99	0.072
Dry mouth [0-100]	0.058	0.51	0.25	0.51	0.92	0.78	0.72
Sticky saliva [0-100]	0.53	0.34	0.50	0.39	0.59	0.046	0.096
Coughing [0-100]	0.074	0.54	0.11	0.14	0.64	0.016	0.16
Felt ill [0-100]	0.66	0.09	0.38	0.42	0.31	0.37	0.64

Painkillers 0.14 0.28 0.79 0.92 0.28 0.14	0.099 0.10
Nutritional cumulaments 0.20 n.a. n.a. 0.41 0.52 0.44	
Nutritional supplements 0.20 n.e. n.e. 0.61 0.53 0.64	
Feeding tube n.e. n.e. n.e. n.e. n.e. n.e.	n.e.
Weight loss 0.77 n.e. <0.001 1.00 n.e. n.e.	0.32
Weight gain 0.38 0.47 0.32 0.16 0.35 0.044	0.40
PASE	
Leisure activity 0.50 0.96 0.034 0.64 0.18 0.43	0.81
Household activity 0.12 0.34 0.65 0.30 0.33 0.81	0.60
Work activity 0.34 0.53 1.00 0.22 0.86 0.38	0.058
Total activity 0.30 0.70 0.20 0.19 0.25 0.85	0.22
Total activity (categorical) 0.27 1.00 0.18 0.31 0.50 0.50	0.24
HADS	
Depression [0-21] 0.53 0.39 0.35 0.33 0.21 0.68	0.33
Anxiety [0-21] 0.65 0.39 0.16 0.24 0.40 0.16	0.20
Total score [0-42] 0.87 0.27 0.18 0.14 0.83 0.35	0.18
CWS	
Fear of recurrence [8-32] 0.22 0.07 0.007 0.73 0.57 0.93	0.061
De Jong Gierveld	
Emotional loneliness score [0-6] 0.29 0.07 0.004 0.63 0.43 0.59	0.003
Social loneliness score [0-5] 0.95 0.60 0.85 0.44 0.50 0.96	0.32
Total loneliness score [0-11] 0.46 0.58 0.09 0.38 0.33 0.65	0.010
Total loneliness score (categorical) 0.29 1.00 0.90 0.27 0.53 0.96	0.21

n.e.=not estimable due to low number of events

Supplemental Table 5A. Stratified estimated marginal means for continous PROMs per assessment and per group, with corresponding estimated changes between 24 (M24) and 36 (M36) months follow-up.

		M36 before COVID			M36 during COVID		
PROM	(sub)group	M24	M36	change	M24	M36	change
EORTC - C30 domain							
Loss of appetite [0-100]	all	7.8	5.6	-2.1	4.8	7.1	2.3
	single modality	6.5	5.6	-0.8	7.9	8.2	0.2
	multimodality	9.5	5.6	-3.9	1.2	5.8	4.6
Financial problems [0-100]	all	5.2	6.3	1.1	5.9	4.6	-1.3
	disease free at M24	3.8	3.6	-0.2	5.7	5.4	-0.3
	residual/recurrence/SP at M24	2.8	11.0	8.3	16.7	10.0	-6.7
EORTC - HN35 domain							
Swallowing [0-100]	all	9.8	9.4	-0.4	7.8	8.9	1.1
	no comorbidity	6.3	8.0	1.7	7.8	7.6	-0.2
	mild comorbidity	10.2	10.8	0.5	7.8	8.1	0.3
	moderate/severe comorbidity	14.7	9.7	-5.0	8.3	13.5	5.2
CWS							
Fear of recurrence [8-32]	all	11.8	11.6	-0.2	11.4	11.5	0.0
	no lifetime depressive disorder at M24	11.1	11.0	-0.1	10.7	10.8	0.0
	lifetime depressive disorder at M24	16.5	14.5	-2.0	13.6	14.5	0.9
De Jong Gierveld							
Emotional loneliness score [0-6]	all	1.0	1.1	0.0	1.1	1.3	0.2
	BMI < median	1.1	1.3	0.2	0.9	0.8	-0.1
	BMI > median	0.9	0.7	-0.2	1.1	1.7	0.5

Supplemental Table 5B. Stratified observed percentage for dichotomous and categorical PROMs per assessment and per group.

			befo	before		during	
PROM		(sub)group	M24	M36	M24	M36	
EORTC - HN35 domain		-					
Painkillers (% yes)		all	26.3%	25.3%	28.7%	26.9%	
		living together at T0	24.8%	20.9%	28.2%	29.6%	
		living alone at T0	33.3%	48.3%	30.0%	18.5%	
PASE							
total score (categorical)	very poor	all	13.9%	17.6%	21.7%	27.3%	
	poor		31.6%	22.9%	23.5%	21.8%	
	fair		21.9%	20.7%	21.7%	15.5%	
	good		12.8%	18.1%	13.9%	15.5%	
	very good		9.6%	8.0%	7.0%	10.9%	
	excelent		10.2%	12.8%	12.2%	9.1%	
	very poor	male	14.7%	19.4%	24.2%	24.1%	
	poor		30.2%	23.3%	22.0%	21.8%	
	fair		19.4%	18.6%	18.7%	13.8%	
	good		14.7%	17.1%	15.4%	17.2%	
	very good		10.1%	9.3%	7.7%	12.6%	
	excelent		10.9%	12.4%	12.1%	10.3%	
	very poor	female	12.1%	13.6%	12.5%	39.1%	
	poor		34.5%	22.0%	29.2%	21.7%	
	fair		27.6%	25.4%	33.3%	21.7%	
	good		8.6%	20.3%	8.3%	8.7%	
	very good		8.6%	5.1%	4.2%	4.3%	
	excelent		8.6%	13.6%	12.5%	4.3%	